{"id":"paxil-cr","safety":{"commonSideEffects":[{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-15%","effect":"Somnolence"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"10-20%","effect":"Sexual dysfunction"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Sweating"}]},"_chembl":{"chemblId":"CHEMBL1628102","moleculeType":"Small molecule","molecularWeight":"468.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paxil-CR (paroxetine controlled-release) inhibits the reuptake of serotonin at presynaptic nerve terminals, leading to increased serotonin concentration in the synaptic space. This enhanced serotonergic neurotransmission is thought to improve mood and reduce anxiety symptoms. The controlled-release formulation provides steady drug levels throughout the day, improving tolerability compared to immediate-release formulations.","oneSentence":"Paxil-CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:54.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Post-traumatic stress disorder"},{"name":"Social anxiety disorder"}]},"trialDetails":[{"nctId":"NCT04961190","phase":"PHASE4","title":"A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-05-25","conditions":"Posttraumatic Stress Disorder","enrollment":302},{"nctId":"NCT06799169","phase":"PHASE4","title":"Management of Acute Tinnitus With Migraine Medications","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-01","conditions":"Tinnitus","enrollment":100},{"nctId":"NCT05431374","phase":"NA","title":"Measurement-Based Care Vs. Standard Care for Major Depressive Disorder","status":"COMPLETED","sponsor":"Pakistan Institute of Living and Learning","startDate":"2022-09-01","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT00581009","phase":"PHASE1, PHASE2","title":"The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2001-05-30","conditions":"Major Depressive Disorder, Bipolar Disorder","enrollment":49},{"nctId":"NCT01416220","phase":"PHASE4","title":"Lithium Versus Paroxetine in Major Depression","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2011-09","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT00841659","phase":"PHASE1","title":"Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT00841698","phase":"PHASE1","title":"Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-10","conditions":"Healthy","enrollment":50},{"nctId":"NCT00648193","phase":"EARLY_PHASE1","title":"Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-12","conditions":"Healthy","enrollment":36},{"nctId":"NCT00648427","phase":"PHASE1","title":"Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-04","conditions":"Healthy","enrollment":75},{"nctId":"NCT00650403","phase":"PHASE1","title":"Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-12","conditions":"Healthy","enrollment":66},{"nctId":"NCT00647881","phase":"PHASE1","title":"Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-04","conditions":"Healthy","enrollment":75},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05637671","phase":"PHASE3","title":"Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-02-10","conditions":"Vasomotor Symptoms","enrollment":146},{"nctId":"NCT04311463","phase":"PHASE1","title":"Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-12-09","conditions":"Anxiety Disorders","enrollment":38},{"nctId":"NCT04981704","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-04-08","conditions":"Healthy","enrollment":74},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT00400088","phase":"PHASE3","title":"Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide","status":"TERMINATED","sponsor":"Nova Scotia Health Authority","startDate":"2007-06","conditions":"Major Depressive Disorder","enrollment":2},{"nctId":"NCT00677352","phase":"PHASE4","title":"A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-05","conditions":"Panic Disorder","enrollment":321},{"nctId":"NCT00463242","phase":"PHASE3","title":"A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Major Depressive Disorder","enrollment":501},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT00292370","phase":"PHASE4","title":"Quetiapine Augmentation for Treatment-resistant PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2006-01","conditions":"Combat Disorders, Stress Disorders, Post-Traumatic","enrollment":124},{"nctId":"NCT00836069","phase":"PHASE3","title":"Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2008-10","conditions":"Anxiety Disorders","enrollment":5},{"nctId":"NCT03504475","phase":"PHASE1","title":"Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2018-03-29","conditions":"Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder","enrollment":53},{"nctId":"NCT00429169","phase":"PHASE4","title":"Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2004-06","conditions":"Depression","enrollment":101},{"nctId":"NCT00246441","phase":"PHASE4","title":"Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2002-03","conditions":"Social Anxiety Disorder, Social Phobia, Alcohol Use Disorder","enrollment":42},{"nctId":"NCT01360866","phase":"PHASE3","title":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2944},{"nctId":"NCT00202449","phase":"NA","title":"Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance","status":"TERMINATED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2004-07","conditions":"Stress Disorders, Post-Traumatic, Sleep Disorders","enrollment":59},{"nctId":"NCT00403455","phase":"PHASE3","title":"Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2006-10","conditions":"PTSD","enrollment":38},{"nctId":"NCT01339247","phase":"PHASE1","title":"Paxil CR Bioequivalence Study Brazil - Fed Administration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-20","conditions":"Depressive Disorder","enrollment":60},{"nctId":"NCT01316926","phase":"PHASE1","title":"Paxil CR Bioequivalence Study Brazil","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-09","conditions":"Depressive Disorder","enrollment":60},{"nctId":"NCT01000857","phase":"PHASE1","title":"Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-05","conditions":"Depressive Disorder","enrollment":26},{"nctId":"NCT01608295","phase":"PHASE4","title":"Vilazodone for Treatment of Geriatric Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2012-07","conditions":"Major Depressive Disorder","enrollment":65},{"nctId":"NCT01748955","phase":"PHASE4","title":"Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-06","conditions":"Depression, Suicidal Ideation","enrollment":15},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT00406003","phase":"PHASE1","title":"Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03-24","conditions":"Depressive Disorder","enrollment":6},{"nctId":"NCT00406432","phase":"PHASE1","title":"A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-09","conditions":"Depressive Disorder","enrollment":12},{"nctId":"NCT00049972","phase":"PHASE4","title":"Major Depressive Disorder Study In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-09","conditions":"Major Depressive Disorder","enrollment":646},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT00749359","phase":"PHASE1","title":"PAXIL CR Bioequivalence Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-07","conditions":"Depressive Disorder","enrollment":166},{"nctId":"NCT01681849","phase":"PHASE4","title":"Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Emory University","startDate":"2009-07","conditions":"PTSD","enrollment":91},{"nctId":"NCT00074802","phase":"PHASE3","title":"Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder","status":"COMPLETED","sponsor":"Temple University","startDate":"2003-12","conditions":"Social Anxiety Disorder","enrollment":150},{"nctId":"NCT01371461","phase":"","title":"Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01","conditions":"Mental Disorders","enrollment":390},{"nctId":"NCT01371435","phase":"","title":"Drug Use Investigation for PAXIL Tablet","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Mental Disorders","enrollment":3708},{"nctId":"NCT01371448","phase":"","title":"Special Drug Use Investigation for PAXIL Tablet (Long-term)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-05","conditions":"Mental Disorders","enrollment":339},{"nctId":"NCT01371474","phase":"","title":"Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Panic Disorder","enrollment":1483},{"nctId":"NCT01376128","phase":"","title":"Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Panic Disorder","enrollment":96},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT00672776","phase":"PHASE4","title":"Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Emory University","startDate":"2003-05","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":40},{"nctId":"NCT00866294","phase":"PHASE3","title":"Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Depressive Disorder","enrollment":416},{"nctId":"NCT00259883","phase":"PHASE4","title":"Combination Of PAXIL Tablet And Benzodiazepines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06","conditions":"Mental Disorders","enrollment":150},{"nctId":"NCT00812812","phase":"PHASE4","title":"Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Depressive Disorder","enrollment":56},{"nctId":"NCT02476136","phase":"","title":"Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis","status":"UNKNOWN","sponsor":"prof. Peter de Jonge","startDate":"2015-05","conditions":"Anxiety Disorders, Panic Disorder, Obsessive-compulsive Disorder","enrollment":8800},{"nctId":"NCT00067444","phase":"PHASE3","title":"Depression Study In Elderly Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Depressive Disorder, Major, Major Depressive Disorder (MDD)","enrollment":560},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT00338962","phase":"PHASE3","title":"Naltrexone & SSRI in Alcoholics With Depression/PTSD","status":"COMPLETED","sponsor":"Yale University","startDate":"2001-10","conditions":"Alcoholism, Depression, PTSD","enrollment":88},{"nctId":"NCT00062738","phase":"PHASE2","title":"Treatment of Depression in Parkinson's Disease Trial","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2003-06","conditions":"Parkinson Disease, Depression","enrollment":52},{"nctId":"NCT02097147","phase":"PHASE1","title":"Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2014-03","conditions":"Healthy","enrollment":202},{"nctId":"NCT00249847","phase":"NA","title":"Study of PET Scans and Serotonin in Hot Flashes Treatment","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Hot Flashes","enrollment":5},{"nctId":"NCT01460212","phase":"PHASE4","title":"Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2011-12","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT01916200","phase":"PHASE4","title":"Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2014-01","conditions":"Depressive Disorder","enrollment":""},{"nctId":"NCT01376271","phase":"","title":"Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01","conditions":"Social Phobia","enrollment":600},{"nctId":"NCT00121888","phase":"PHASE1, PHASE2","title":"Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2002-12","conditions":"Stress Disorders, Post-Traumatic","enrollment":60},{"nctId":"NCT00700999","phase":"PHASE4","title":"Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2008-10","conditions":"Post-traumatic Stress Disorder","enrollment":65},{"nctId":"NCT00113295","phase":"PHASE4","title":"Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-02","conditions":"Anxiety Disorder","enrollment":50},{"nctId":"NCT00610909","phase":"PHASE4","title":"Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-01","conditions":"Irritable Bowel Syndrome","enrollment":60},{"nctId":"NCT00610610","phase":"PHASE4","title":"Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-01","conditions":"Fibromyalgia Syndrome","enrollment":120},{"nctId":"NCT00215163","phase":"PHASE2, PHASE3","title":"Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-12","conditions":"Stress Disorders, Post-Traumatic","enrollment":17},{"nctId":"NCT01831440","phase":"NA","title":"Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2011-01","conditions":"Depressive Disorder","enrollment":200},{"nctId":"NCT00086190","phase":"PHASE3","title":"Study of Antidepressants in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2005-06","conditions":"Parkinson Disease, Depression","enrollment":115},{"nctId":"NCT01130103","phase":"PHASE4","title":"Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack","status":"COMPLETED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2004-03","conditions":"Posttraumatic Stress Disorder","enrollment":37},{"nctId":"NCT01357967","phase":"PHASE4","title":"The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope","status":"UNKNOWN","sponsor":"Inje University","startDate":"2011-05","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT00368303","phase":"PHASE3","title":"A Local Register Study For Major Depression Of Paroxetine Controlled Release","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Depressive Disorder, Major, Major Depressive Disorder (MDD)","enrollment":362},{"nctId":"NCT00767754","phase":"PHASE4","title":"Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2007-01","conditions":"Panic Disorder","enrollment":37},{"nctId":"NCT00225914","phase":"PHASE4","title":"Study of Paxil Use in Menopausal Women","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-09","conditions":"Menopause","enrollment":64},{"nctId":"NCT00261729","phase":"NA","title":"Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2004-07","conditions":"Sleep Disorders, Stress Disorders, Post-Traumatic","enrollment":210},{"nctId":"NCT00901407","phase":"NA","title":"Lamotrigine Augmentation in Resistant Depression","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2003-12","conditions":"Unipolar Depression","enrollment":138},{"nctId":"NCT00680602","phase":"PHASE4","title":"Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2006-01","conditions":"Obsessive Compulsive Disorder","enrollment":158},{"nctId":"NCT00715039","phase":"NA","title":"Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Anxiety Disorders","enrollment":169},{"nctId":"NCT00229528","phase":"PHASE4","title":"Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2004-03","conditions":"Coronary Artery Disease","enrollment":25},{"nctId":"NCT00330239","phase":"PHASE4","title":"Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-01","conditions":"PTSD","enrollment":25},{"nctId":"NCT00492414","phase":"PHASE4","title":"Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release","status":"UNKNOWN","sponsor":"Inje University","startDate":"","conditions":"Panic Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":782,"reaction":"DRUG INEFFECTIVE"},{"count":588,"reaction":"DIZZINESS"},{"count":507,"reaction":"NAUSEA"},{"count":496,"reaction":"DRUG WITHDRAWAL SYNDROME"},{"count":493,"reaction":"ANXIETY"},{"count":436,"reaction":"DRUG EXPOSURE DURING PREGNANCY"},{"count":393,"reaction":"HEADACHE"},{"count":362,"reaction":"INSOMNIA"},{"count":330,"reaction":"DEPRESSION"},{"count":310,"reaction":"WEIGHT INCREASED"}],"_approvalHistory":[{"date":"20050112","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20031016","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20240223","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20230818","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20020212","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20140718","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20010430","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20190911","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20090717","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20000718","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20170104","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20121218","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20000817","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20081031","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20070802","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20110321","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20090807","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20060206","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20101027","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20040521","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20060822","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20060822","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20060309","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20040127","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20020722","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20030828","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20230818","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20010430","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20001206","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20120410","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20210920","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20000921","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20090130","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20110708","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"19990702","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"19990216","type":"ORIG","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20110708","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20060206","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20110321","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20050713","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20060822","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"},{"date":"20060206","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"NDA020936"}],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Paxil-CR","genericName":"Paxil-CR","companyName":"University of Oklahoma","companyId":"university-of-oklahoma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paxil-CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}